Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage

Pharmaceuticals
Jumpei FujikiHidetomo Iwano

Abstract

Antibiotic-resistant bacteria (ARB) have spread widely and rapidly, with their increased occurrence corresponding with the increased use of antibiotics. Infections caused byStaphylococcus aureushave a considerable negative impact on human and livestock health. Bacteriophages and their peptidoglycan hydrolytic enzymes (endolysins) have received significant attention as novel approaches against ARB, includingS. aureus. In the present study, we purified an endolysin, Lys-phiSA012, which harbors a cysteine/histidine-dependent amidohydrolase/peptidase (CHAP) domain, an amidase domain, and a SH3b cell wall binding domain, derived from a polyvalentS. aureusbacteriophage which we reported previously. We demonstrate that Lys-phiSA012 exhibits high lytic activity towards staphylococcal strains, including methicillin-resistantS. aureus(MRSA). Analysis of deletion mutants showed that only mutants possessing the CHAP and SH3b domains could lyseS. aureus, indicating that lytic activity of the CHAP domain depended on the SH3b domain. The presence of at least 1 mM Ca2+and 100 µM Zn2+enhanced the lytic activity of Lys-phiSA012 in a turbidity reduction assay. Furthermore, a minimum inhibitory concentration (MIC) assay showed that the addition of...Continue Reading

References

Apr 14, 2000·Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health·E O CostaP A Melville
Aug 23, 2002·Nature·Raymond SchuchVincent A Fischetti
Dec 5, 2002·Journal of Mammary Gland Biology and Neoplasia·Lorraine M Sordillo, Katie L Streicher
Jun 14, 2003·TheScientificWorldJournal·F Bronner
Jun 18, 2004·Emerging Infectious Diseases·Hélène Aubry-DamonAntoine Andremont
Aug 30, 2005·Trends in Microbiology·Vincent A Fischetti
Nov 1, 2005·The Journal of Biological Chemistry·Jeff Zhiqiang LuJoshua Sakon
Nov 23, 2005·Bioinformatics·Konstantin ArnoldTorsten Schwede
Oct 24, 2006·FEMS Microbiology Letters·David M DonovanJuli Foster-Frey
Oct 24, 2007·The Journal of Infectious Diseases·Mohammad RashelShigenobu Matsuzaki
Nov 21, 2007·Veterinary Microbiology·T KhannaJ S Weese
Mar 20, 2008·Annual Review of Public Health·Ellen K SilbergeldLance B Price
Aug 30, 2008·FEMS Microbiology Letters·Stephen C BeckerDavid M Donovan
Oct 14, 2008·Expert Review of Anti-infective Therapy·Lisa L MaragakisSara E Cosgrove
Oct 22, 2008·Nucleic Acids Research·Florian KieferTorsten Schwede
Jun 6, 2009·FEMS Microbiology Letters·Stephen C BeckerDavid M Donovan
Jul 25, 2009·Emerging Infectious Diseases·Olivier DenisMarc J Struelens
Jul 14, 2010·Applied and Environmental Microbiology·Mathias SchmelcherMartin J Loessner
Jan 26, 2011·Antimicrobial Agents and Chemotherapy·Soo Youn JunSang Hyeon Kang
Jul 13, 2011·Antimicrobial Agents and Chemotherapy·Mirian DomenechMiriam Moscoso
Jun 14, 2012·Environmental Monitoring and Assessment·Yan-Xia LiJing Wang
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Dec 19, 2013·Frontiers in Microbiology·Sean Meaden, Britt Koskella
Dec 25, 2013·International Journal of Medical Microbiology : IJMM·Bettina LöfflerGeorg Peters

❮ Previous
Next ❯

Citations

May 6, 2020·Virus Genes·Jasjeet KaurSanjay Chhibber
Apr 19, 2019·Applied Microbiology and Biotechnology·Aa Haeruman Azam, Yasunori Tanji
Dec 3, 2020·Expert Review of Anti-infective Therapy·Amrita PatilSunil Saroj
Nov 13, 2019·International Journal of Antimicrobial Agents·Vijay Singh GondilSanjay Chhibber
Oct 5, 2020·Infectious Disease Clinics of North America·Richard R Watkins, Robert A Bonomo
May 18, 2021·Frontiers in Molecular Biosciences·Lauren WalshR Paul Ross
Jul 10, 2021·Applied Microbiology and Biotechnology·Yanhua JiangLin Yao
Aug 13, 2021·The Journal of Microbiology·Jun-Hyeok YuJong-Hyun Park

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
PCR

Software Mentioned

IPLA
RODI
BLAST
MODEL
InterPro
GENETYX
SWISS

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.